DBEI | CCEB  |  Intranet

John H. Kempen, MD, MPH, MHS, PhD



John H. Kempen, MD, MPH, MHS, PhD

Professor of Ophthalmology

Dr. Kempen’s research focuses on the safety and effectiveness of treatments for ocular inflammatory diseases and ocular infectious diseases, particularly those related to HIV/AIDS. He also is active in identifying factors predictive of unfavorable outcomes of these diseases, which might be modifiable to avoid bad outcomes, or might alter current clinical management of these patients. Major topics of interest include evaluation of the long-term risks of immunosuppressive therapy, comparison of alternative treatment paradigms for the treatment of uveitis, development of new treatments for non-infectious scleritis, and management of patients with AIDS and cytomegalovirus retinitis. Major current studies include the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study (which has demonstrated that immunosuppression with antimetabolites or cyclosporine does not increase the risk of mortality over a median of five to seven years’ follow-up) and the Multicenter Uveitis Steroid Treatment (MUST) Trial (which has demonstrated systemic therapy with corticosteroids and immunosuppression when indicated has similar visual outcomes to fluocinolone acetonide implant therapy over two years).

Dr. Kempen has recently begun an initiative to evaluate electophoretic delivery of dexamethasone phosphate for treatment of scleritis. He is active in developing research and clinical infrastructure (as applied to ophthalmology) in developing countries.

Content Area Specialties

Ophthalmological epidemiology

Share this Content

About Us

To understand health and disease today, we need new thinking and novel science —the kind  we create when multiple disciplines work together from the ground up. That is why this department has put forward a bold vision in population science: a single academic home for biostatistics, epidemiology and informatics. MORE

© 2017 Trustees of the University of Pennsylvania. All rights reserved.

Follow Us